C - Chemistry – Metallurgy – 12 – N
Patent
C - Chemistry, Metallurgy
12
N
C12N 5/10 (2006.01) A01K 67/027 (2006.01) A61K 31/00 (2006.01) A61K 39/395 (2006.01) C07K 14/47 (2006.01) C07K 14/515 (2006.01) C07K 16/18 (2006.01) C12Q 1/00 (2006.01) C12Q 1/02 (2006.01) G01N 33/50 (2006.01) C12Q 1/68 (2006.01)
Patent
CA 2601677
The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO179, PRO181, PRO244, PRO247, PRO269, PRO293, PRO298, PRO339, PRO341, PRO347, PRO531, PRO537, PRO718, PRO773, PRO860, PRO871, PRO872, PRO813, PRO828, PRO1100, PRO1114, PRO1115, PRO1126, PRO1133, PRO1154, PRO1185, PRO1194, PRO1287, PRO1291, PRO1293, PRO1310, PRO1312, PRO1335, PRO1339, PRO2155, PRO1356, PRO1385, PRO1412, PRO1487, PRO1758, PRO1779, PRO1785, PRO1889, PRO90318, PRO3434, PRO3579, PRO4322, PRO4343, PRO4347, PRO4403, PRO4976, PRO260, PRO6014, PRO6027, PRO6181, PRO6714, PRO9922, PRO7179, PRO7476, PRO9824, PRO19814, PRO19836, PRO20088, PRO70789, PRO50298, PRO51592, PRO1757, PRO4421, PRO9903, PRO1106, PRO1411, PRO1486, PRO1565, PRO4399 or PRO4404 genes. Such in vivo studies and characterizations may provide valuable identification and discovery of therapeutics and/or treatments useful in the prevention, amelioration or correction of diseases or dysfunctions associated with gene disruptions such as neurological disorders; cardiovascular, endothelial or angiogenic disorders; eye abnormalities; immunological disorders; oncological disorders; bone metabolic abnormalities or disorders; lipid metabolic disorders; or developmental abnormalities.
La présente invention concerne des animaux transgéniques ainsi que des compositions et des méthodes en rapport avec la caractérisation de la fonction génique. Spécifiquement, cette invention concerne des souris transgéniques présentant des disruptions dans les gènes PRO179, PRO181, PRO244, PRO247, PRO269, PRO293, PRO298, PRO339, PRO341, PRO347, PRO531, PRO537, PRO718, PRO773, PRO860, PRO871, PRO872, PRO813, PRO828, PRO1100, PRO1114, PRO1115, PRO1126, PRO1133, PRO1154, PRO1185, PRO1194, PRO1287, PRO1291, PRO1293, PRO1310, PRO1312, PRO1335, PRO1339, PRO2155, PRO1356, PRO1385, PRO1412, PRO1487, PRO1758, PRO1779, PRO1785, PRO1889, PRO90318, PRO3434, PRO3579, PRO4322, PRO4343, PRO4347, PRO4403, PRO4976, PRO260, PRO6014, PRO6027, PRO6181, PRO6714, PRO9922, PRO7179, PRO7476, PRO9824, PRO19814, PRO19836, PRO20088, PRO70789, PRO50298, PRO51592, PRO1757, PRO4421, PRO9903, PRO1106, PRO1411, PRO1486, PRO1565, PRO4399 ou PRO4404. De telles études et caractérisations in vivo peuvent conduire à des identifications précieuses et à la découverte d'agents thérapeutiques et/ou de traitements utiles pour la prévention, l'amélioration ou l'infléchissement de maladies et ou de dysfonctionnements en rapport avec des disruptions géniques, tels que des troubles neurologiques, des troubles cardio-vasculaires, endothéliaux ou angiogènes; des anomalies oculaires, des troubles de l'immunologie, des troubles oncologiques, des anomalies ou des troubles du métabolisme osseux, des troubles du métabolisme des lipides ou des anomalies du développement
Clarke Catherine Anne B.
Combs Katherin E.
Desauvage Frederic
Ding Zhiyong
Edwards Joel
Genentech Inc.
Lexicon Pharmaceuticals Inc.
Smart & Biggar
LandOfFree
Gene disruptions, compositions and methods relating thereto does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Gene disruptions, compositions and methods relating thereto, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Gene disruptions, compositions and methods relating thereto will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1541235